Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

http://www.wikidata.org/entity/Q45323441

about

Lymphangioleiomyomatosis: differential diagnosis and optimal management Management of lymphangioleiomyomatosis Diffuse Cystic Lung Disease. Part I.Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis.Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.Lung Transplantation for Lymphangioleiomyomatosis in Japan.Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.Isolation of individual cellular components from lung tissues of patients with lymphangioleiomyomatosis.Transudative chylothorax in a patient with lymphangioleiomyomatosis.Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.Chronic sirolimus therapy for lymphangioleiomyomatosis.Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus.Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?Recent advances in the management of lymphangioleiomyomatosis.Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis

P2860

Q27022412-50F3A0A7-9101-4971-B424-21BCC42CE849 Q28084725-7CBA7A57-FFC9-49C1-A482-C253701A633A Q33722950-7B973AE4-AF72-4B93-906E-B665B5300463 Q34365375-B84902A0-02A8-4964-97A2-887C7CD04A17 Q35657827-A04831DB-6B0B-4D84-9F6D-55BD52850C87 Q35895325-DD8CE563-5FED-4FCC-8B2C-5D6D69F0495D Q35971499-C3AD131F-02FD-4E9D-8410-8458D23E84C0 Q36462100-725BED65-37A9-45D4-9050-7C313936B606 Q37193373-E1AA6AA5-E50E-4944-ABAC-8FD038715384 Q37697798-CDD83A16-A756-4669-969E-49968427C90E Q38372196-53105D5F-001F-4899-BAB4-077C83B9FC24 Q39500474-E7479D34-5FBF-43F1-AA31-D9CB3986BFCA Q40740177-01734115-9D9C-4609-8575-F6F48E99BD12 Q45070834-6C2C9441-F12A-43A1-99B1-D769CB74A7A3 Q47370738-7CC5E1F7-6B17-4785-AE87-D7C616F5CCE3 Q47662133-6596CEEB-4C8B-43A4-87BC-5C2685A12283 Q48008829-1C992850-E89D-4D22-85E1-7438344EE8D2 Q48355779-1B9F9836-ECCB-4BFE-B528-02692F32D86E Q49783838-F4089181-354D-4479-BED4-AD873F0A8EEC Q49843469-BF6478FE-3131-423C-873D-ECFBC83DED4F Q53022016-8A986903-8817-4678-A223-F8B25E57CA61 Q55483958-BA261C07-3F33-4251-B203-97183926DEC6 Q59126578-7C82246D-DD02-4867-A705-A0FF6515803E

P2860

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

http://www.wikidata.org/entity/Q45323441

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

@en

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

@nl

type

label

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

@en

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

@nl

prefLabel

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

@en

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

@nl

P1433

Q45323441-1C8E952C-24CF-46FA-854A-43CE7F3683C0

P1476

Q45323441-CBA02B09-2510-401D-BADD-C4E7EFF476CB

P2093

Q45323441-060BBDEC-60D7-47C0-AC07-AB454F74EE22

Q45323441-32723A2E-7443-435B-B3DF-520661A2F1C0

Q45323441-33F3BD99-7A74-45A4-937B-69D641452451

Q45323441-397733F2-DFB3-4DAF-B2A1-9C5EEBD60AA0

Q45323441-553A62FF-F498-459A-AD64-CA2B94B09953

Q45323441-747F8D8E-E09D-4FD7-A1D8-5C5E77735CF2

Q45323441-88ED1A48-BB67-4AF9-9BE1-EFB4E14EB0FF

Q45323441-B2626A25-B001-4848-849D-7F9AA7D121B0

Q45323441-C000B09D-8EB5-4758-95C8-7D29B39DABD5

Q45323441-DA65291D-46BA-4121-8C97-D828C092691B

P304

Q45323441-23364F39-B287-4408-8C0C-D2C2ADF2B953

P31

Q45323441-3268C072-35B4-4F2A-ACD6-6043BDAF03E0

P356

Q45323441-D5225096-CEC6-4247-87E8-CBD0529CE782

P433

Q45323441-8FBBE353-0368-4E46-83E4-1130D43F5504

P478

Q45323441-80A85C6C-DA82-4689-86BF-2112CDCEE2FC

P577

Q45323441-894A99ED-469C-4247-9CD5-485DF58292B5

P698

Q45323441-0261E155-3251-48FE-A0AE-4A0BC909D6C7

P356

J.RESINV.2013.03.002

P1433

Respiratory investigation

P1476

Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.

@en

P2093

Hideyuki Kataoka

http://www.w3.org/2001/XMLSchema#string

Katsutoshi Ando

http://www.w3.org/2001/XMLSchema#string

Kazuhisa Takahashi

http://www.w3.org/2001/XMLSchema#string

Kuniaki Seyama

http://www.w3.org/2001/XMLSchema#string

Masako Ueyama

http://www.w3.org/2001/XMLSchema#string

Masashi Mikami

http://www.w3.org/2001/XMLSchema#string

Masatoshi Kurihara

http://www.w3.org/2001/XMLSchema#string

Shin-ichiro Iwakami

http://www.w3.org/2001/XMLSchema#string

Shinsaku Togo

http://www.w3.org/2001/XMLSchema#string

Teruhiko Sato

http://www.w3.org/2001/XMLSchema#string

P304

175-183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.RESINV.2013.03.002

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23978644

http://www.w3.org/2001/XMLSchema#string